User menu

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

Bibliographic reference Goffette, Sophie ; Van Pesch, Vincent ; Vanoverschelde, Jean-Louis ; Morandini, Emmanuel ; Sindic, Christian. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.. In: Journal of Neurology : official journal of the European Neurological Society, Vol. 252, no. 10, p. 1217-1222 (2005)
Permanent URL http://hdl.handle.net/2078.1/10162
  1. Posner LE, Dukart G, Goldberg J, et al. (1985) Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3:123–132
  2. Stern Y., Tetrud J. W., Martin W.R.W., Kutner S. J., Langston J. W., Cognitive change following MPTP exposure, 10.1212/wnl.40.2.261
  3. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H (1992) Treatment of Multiple Sclerosis with Mitoxantrone. Eur Arch Psychiatry Clin Neurosci 242:96–102
  4. Kappos L, Gold R, Kündtler E, et al. (1990) Mitoxantrone in the treatment of rapidly progressive MS: a pilot study with serial gadolinium-enhanced MRI. Neurology 40(Suppl 1): 261. Abstract. (539 P)
  5. Noseworthy J. H., Hopkins M. B., Vandervoort M. K., Karlik S. J., Lee D. H., Penman M., Rice G.P.A., Grinwich K. D., Cauvier H., Harris B. J., Ebers G. C., An open-trial evaluation of mitoxantrone in the treatment of progressive MS, 10.1212/wnl.43.7.1401
  6. Millefiorini E, Gasperini C, Pozzilli C, et al. (1997) Randomized placebo-controlled trial mitoxantrone in relapsingremitting multiple sclerosis: a 24- month clinical and MRI outcome. J Neurol 244:153–159
  7. Edan G, Miller D, Clanet M, et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112–118
  8. van de Wyngaert FA, Beguin C, D’Hooghe MB, et al. (2001) A doubleblind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 101: 210–216
  9. Hartung HP, Gonsette R, König N, et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018–2025
  10. Gonsette RE (1996) Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1:329–332
  11. Edan G, Brochet B, Clanet M, et al. (2004) Safety profile of mitoxantrone in a cohort of 802 MS patients. A for year follow-up study. Neurology 62(Suppl 5): P 06093 Abstract
  12. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents. Drug Safety 22:263–302
  13. Unverferth DV, Unfervert BJ, Balcerzak SP, Bashore TA, Neidhart JA (1983) Cardiac evaluation of mitoxantrone. Cancer Treat Rep 67:343–350
  14. Keefe DL (2001) Anthracycline-induced cardiomyopathy. Semin Oncol 28(4 Suppl 12):2–7
  15. Herman EH, Zhang J, Hasinoff BB, Clark JR, Ferrans VJ (1997) Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe (III)-mitoxantrone complex. J Mol Cell Cardiol 29:2415–2430
  16. Andersson BS, Eksborg S, Vidal RF, Sundberg M, Carlberg M (1999) Anthraquinone- induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. Toxicology 135:11–20
  17. Gonsette RE (2003) Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 206:203–208
  18. Steinherz LJ, Steinherz PG, Mangiacasale D, et al. (1981) Cardiac changes with cyclophosphamide. Med Pediatr Oncol 9:417–422
  19. Cazin B, Gorin NC, Laporte JP, et al. (1986) Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 57:2061–2069
  20. Feuillet L, Guedj E, Eusibio A, et al. (2003) Insuffisance cardiaque aiguë chez une patiente traitée par mitoxantrone pour sclérose en plaques. Rev Neurol (Paris) 159:1169–1172
  21. McDougall AJ, McLeod JG (2003) Autonomic nervous system function in multiple sclerosis. J Neurol Sci 215:79–85
  22. Olindo S, Guillon B, Helias J, Phillibert B, Magne C, Fève JR (2002) Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur J Neurol 9:287–291
  23. Beer M, Sandstede J, Weilbach F, et al. (2001) Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 173:399–404
  24. Mauch E, Eisenmann S, Hahn A (1999) Mitoxantrone in the treatment of patients with multiple sclerosis(MS): a large single-center experience. Mult Scler 5(Suppl 1):S94
  25. Ghalie RG, Edan G, Laurent M, et al. (2002) Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59:909–913
  26. The Euro Heart Failure Survey Programme (2003) A survey on the quality of care among patients with heart failure in Europe. Eur Heart J 24:422–474
  27. Aviles A, Arevila N, Diaz Maqueo JC, Gomez T, Garcia R, Jesus Nambo MA (1993) Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin’s disease in adults. Leuk Lymphoma 11:275–279
  28. Ritchie JL, Singer JW, Thorning D, Sorensen SG, Hamilton GW (1980) Anthracycline cardiotoxicity: clinical and pathological outcomes assessed by radionuclide ejection fraction. Cancer 46:1109
  29. Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE (2003) Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 9:59–62
  30. De Castro Stefano, Cartoni Domenico, Millefiorini Enrico, Funaro Stefania, Gasperini Claudio, Morino Stefania, Tallarico Demetrio, Beni Sergio, Noninvasive Assessment of Mitoxantrone Cardiotoxicity in Relapsing Remitting Multiple Sclerosis, 10.1002/j.1552-4604.1995.tb05021.x
  31. Villani F, Galimberti M, Crippa F (1989) Evaluation of ventricular function by echography and radionuclide angiography in patients treated with mitoxantrone. Drugs Exp Clin Res 15:501–506
  32. Strotmann JM, Spindler M, Weilbach FX, Gold R, Ertl G, Voelker W (2002) Myocardial function in patients with multiple sclerosis treated with lowdose mitoxantrone. Am J Cardiol 89:1222–1225